Results 61 to 70 of about 11,568,194 (143)

Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization

, 2013
Inflammatory processes are important in the pathogenesis of Alzheimer's disease and in response to amyloid-β immunotherapy. We investigated the expression of multiple inflammatory markers in the brains of 28 non-immunized patients with Alzheimer's ...
Cheaveau, M., Morgan, William, Cheaveau, Matthew, Boche, Delphine, Bharambe, V., Holmes, C., Love, S., Nicoll, James A R, Harris, Scott, Bharambe, Viraj, Neal, James W, Love, Seth, Nicoll, J.A.R., Zotova, E., Boche, D., Morgan, W., Neal, J.W., Holmes, Clive, Zotova, Elina   +18 more
core   +1 more source

CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer's disease patients. [PDF]

Alzheimers Res Ther
BACKGROUND: Amyloid-related imaging abnormalities (ARIA) are a common and potentially dangerous side effect in anti-amyloid therapies, creating a need for tools to assess ARIA risk.
Oosthoek M, Vijverberg EGB, Blujdea ER, Veld SGJGI, Avilés MP, Zsadanyi SE, Hok-A-Hin YS, Visser A, van der Flier WM, Barkhof F, Del Campo M, Schut MC, Bejanin A, Alcolea D, Teunissen CE, Vermunt L.   +15 more
europepmc   +3 more sources

Real—world application of lecanemab in early—stage alzheimer's disease: a single—center prospective cohort analysis

Alzheimer’s Research & Therapy
Background and objectives Lecanemab (Leqembi®) has been approved for the treatment of early Alzheimer’s disease (AD) patients. However, the safety and efficacy of lecanemab in clinical practice in Asia population remain unclear.
Jia Shang, Siyan Zhong, Li Shang, Qingze Zeng, Shuai Zhao, Xiao Luo, Kaicheng Li, Xinyi Zhang, Peiyu Huang, Yaping Yan, Zhirong Liu, Baorong Zhang, Yanxing Chen   +12 more
doaj   +1 more source

Fibril fragmentation in amyloid assembly and cytotoxicity: When size matters [PDF]

, 2010
Amyloid assemblies are associated with several debilitating human disorders. Understanding the intra- and extracellular assembly of normally soluble proteins and peptides into amyloid aggregates and how they disrupt normal cellular functions is therefore
Xue, Wei-Feng, Hellewell, Andrew L., Hewitt, Eric W., Radford, Sheena E., Eric W. Hewitt, Andrew L. Hellewell, Wei-Feng Xue, Sheena E. Radford   +7 more
core   +1 more source

Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms

Three monoclonal antibodies directed against specific forms of the amyloid-β (Aβ) peptide have been granted accelerated or traditional approval by the FDA as treatments for Alzheimer disease, representing the first step towards bringing disease-modifying
Greenberg S. M., van Veluw S. J., Bax F., Bax, F.   +3 more
core   +1 more source

Regional distribution of amyloid-Bri deposition and its association with neurofibrillary degeneration in familial British dementia [PDF]

, 2001
Familial British dementia (FBD), pathologically characterized by cerebral amyloid angiopathy (CAA), amyloid plaques, and neurofibrillary degeneration, is associated with a stop codon mutation in the BRI gene resulting in the production of an ...
Tammaryn Lashley, Ghiso, J, Vidal, R, Ayling, H., Gibb, G, Anderton, B H, Hilary Ayling, Rostagno, A., Anderton, B.H., Plant, G., Janice L. Holton, Tamas Revesz, Revesz, T, Martinian, L, Henry Houlden, Ruben Vidal, Nicholas W. Wood, Lashley, T, Revesz, T., Frangione, B., Jorge Ghiso, Ayling, H, Holton, J.L., Christopher J. Guerin, Houlden, H, Plant, G, Holton, J L, Gordon Plant, Rostagno, A, Lashle, T., Gibb, G., Lillian Martinian, Ghiso, J., Graham Gibb, Martinian, L., Brian H. Anderton, Agueda Rostagno, Houlden, H., Wood, N.W., Frangione, B, Vidal, R., Guerin, C J, Wood, N W, Guerin, C.J., Blas Frangione   +44 more
core   +1 more source

Table1_Imaging spectrum of amyloid-related imaging abnormalities associated with aducanumab immunotherapy.docx

Alzheimer's Disease (AD) is a leading cause of morbidity. Management of AD has traditionally been aimed at symptom relief rather than disease modification.
Manoj Tanwar (17737653), C. Austin Wheeler (17737647), Parnian Shobeiri (9117877), Marissa Natelson Love (17737650), Ramin Shahidi (16805001), Zahra Saadatpour (17737644), Mohammadreza Alizadeh (17737641), Houman Sotoudeh (14786503)   +7 more
core   +1 more source

The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer’s Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective

Diagnostics
Amyloid positron emission tomography (PET) has become a critical tool in the diagnosis and treatment of Alzheimer’s disease (AD). The Centiloid (CL) scale, a tracer/scanner-independent, standardized quantification unit introduced in 2015, transforms ...
Houman Sotoudeh, Mohammadreza Alizadeh
doaj   +1 more source

A Genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology [PDF]

, 2015
We provide microarray data comparing genome-wide differential expression and pathology throughout life in four lines of "amyloid" transgenic mice (mutant human APP, PSEN1, or APP/PSEN1) and "TAU" transgenic mice (mutant human MAPT gene).
Cummings, DM, Moens, TG, Fulleylove, M, Liu, W, Latcham, J, Smith, KJ, NahabooSolim, MA, Edwards, FA, Desai, R, Ali, SS, Matarin, M, Paublete, RM, Perona, M, Salih, DA, Guelfi, S, Richardson, JC, Yasvoina, M, Hardy, J   +17 more
core  

How many sites are enough? a novel, site-based power analysis method for real-world registry studies of anti-amyloid monoclonal antibodies

JAR Life
Background: Real-world registries ALZ-NET (US) and AD-DMT (Japan) support safety surveillance of anti-amyloid antibodies. Conventional power calculations—dividing required patients by mean per-site caseload—can underestimate the number of centers needed ...
Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Takeshi Iwatsubo   +4 more
doaj   +1 more source